Innovage Holding Corp.

Innovage Holding Corp. (INNV) Market Cap

Innovage Holding Corp. has a market capitalization of $1.54B.

Price: $11.36

-0.24 (-2.07%)

Market Cap: 1.54B

NASDAQ · time unavailable

CEO: Patrick Blair

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2021-03-04

Website: https://www.innovage.com

Innovage Holding Corp. (INNV) - Company Information

Market Cap: 1.54B|Sector: Healthcare

Company Profile

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to and from the PACE center and third-party medical appointments; and care management. It serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 1989 and is headquartered in Denver, Colorado.

Analyst Sentiment

18%
Underperform

From 3 Active Polls

1Y Forecast: $6.80

▼ -40.1% Potential Upside

Consensus Target Metrics

Low Bound

$5

Median

$8

High Bound

$8

Average

$7

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$6.80
▼ -40.14% Upside
Low Target
$5.00
-56% Risk
Median Target
$8.00
-30% Mid
High Target
$8.00
-30% Max
Consensus
Hold
0 / 8 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,5421,088704698499403532815686
Enterprise Value ($M)1,5401,087738729536448593886742
Price to Earnings Ratio (P/E)-37.65-9.1116.57-16.13-11.53-8.85-9.82-37.50-100.80
Price/Earnings-to-Growth Ratio (PEG)-1.7910.86-1.96-2.02-5.23-13.02-30.74
Price to Sales Ratio (P/S)1.634.322.942.952.291.852.553.973.44
Price to Book Ratio (P/B)6.734.752.742.852.121.692.143.122.55
Price to Free Cash Flow Ratio (P/FCF)39.6774.4737.07-4559.7092.2218.5498.39-83.84-478.74
Enterprise Value to Sales (EV/Sales)4.313.083.092.462.052.844.323.72
Enterprise Value to EBITDA (EV/EBITDA)353.68-45.3539.7251.12-118.68-99.18-80.33657.42128.16
Debt to Equity Ratio-0.390.410.460.400.430.440.430.420.42

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

```html

📘 INNOVAGE HOLDING CORP (INNV) — Investment Overview

🧩 Business Model Overview

InnovAge is a senior-focused healthcare provider that delivers care through an integrated model spanning clinical services, care management, and payer-facing arrangements tied to government reimbursement (notably Medicare-based programs such as value-based and capitated structures, depending on program mix). The operating logic is to coordinate multidisciplinary care for older adults—often in-home and community settings—aiming to reduce avoidable utilization (e.g., preventable hospitalizations) while meeting quality and regulatory requirements.

This structure creates practical “stickiness” through continuity of care: once members/patients and their families receive a coordinated care plan, transitions are operationally and clinically disruptive. Over time, InnovAge builds internal care pathways, provider partnerships, and payer-approved processes that support consistent delivery and documentation—critical in government-reimbursement environments.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by government program reimbursements and patient-member service volumes, typically with a meaningfully recurring component when tied to capitated or managed-care style arrangements. Service lines often include ongoing clinical care and care management activities, with additional revenue from utilization-dependent services.

Margin drivers tend to be:

  • Care model efficiency: improved care coordination that limits costly acute utilization.
  • Reimbursement quality: the ability to sustain eligibility and performance metrics that protect revenue yield.
  • Workforce and delivery costs: labor intensity of care delivery and the efficiency of scheduling and care-team utilization.
  • Program mix: the balance between more predictable managed/per-member economics versus more variable fee-for-service components.

🧠 Competitive Advantages & Market Positioning

InnovAge’s core moat is regulatory + operational barrier to entry combined with an integrated care ecosystem.

  • Regulatory moat (high barriers to entry): Senior programs tied to government reimbursement require approvals, ongoing compliance, documentation, and performance oversight. Establishing and maintaining these credentials is not easily replicable and typically requires years of operating history, process maturity, and staff capability.
  • Integrated ecosystem (care pathways + continuity): Coordinated multidisciplinary care (clinical, management, and member support) supports downstream outcomes and documentation needed for ongoing payer/program participation.
  • Quality-driven economics: In value-based/capitated contexts, reimbursement is sensitive to outcomes and risk profile management. This shifts competition toward care effectiveness, not just capacity.

Competitive benchmarking (primary competitors):

  • Amedisys (home health-focused): Predominantly structured around episodic/clinical services delivery. InnovAge’s differentiation is the integrated, program-linked care model with stronger emphasis on coordinated management across a member lifecycle.
  • Addus HomeCare (home care/services): Similar delivery orientation, but often less embedded in a tightly coordinated, payer-governed integrated ecosystem. InnovAge’s advantage is the ability to operationalize program performance requirements within a managed-care style framework.
  • SC S/H-type PACE or Medicare program operators (e.g., SCAN Health Plan in PACE contexts): Competes where the focus is senior-program integration and regulatory participation. InnovAge’s positioning centers on its specific network of clinical delivery, care management workflows, and the particular geographies and program relationships it manages.

🚀 Multi-Year Growth Drivers

Sustainable growth over a 5–10 year horizon is primarily supported by secular demand and program economics:

  • Demographic tailwinds: Aging populations increase the need for coordinated geriatric care, home/community-based delivery, and chronic-condition management.
  • Shift toward value-based care: Payers and regulators continue to push outcomes- and cost-of-care-aligned reimbursement models, favoring providers that can manage utilization and quality simultaneously.
  • Program expansion and contract durability: Incremental growth can come from participating in additional government programs/regions, deepening existing membership, and maintaining performance that supports continued participation.
  • Operational scaling: As member volumes rise, integrated care workflows and care-team processes can spread fixed costs (clinical leadership, compliance operations, care management tooling) across a larger base—supporting margin resilience when managed effectively.

⚠ Risk Factors to Monitor

  • Reimbursement and policy risk: Changes to Medicare/Medicaid rules, risk adjustment methodologies, quality program requirements, or reimbursement rates can alter economics.
  • Utilization and risk-profile variability: In capitated/value-based settings, adverse member mix or higher-than-expected utilization can pressure margins.
  • Quality and compliance risk: Regulatory noncompliance, documentation gaps, or failure to meet performance metrics can affect eligibility and revenue.
  • Labor cost and staffing constraints: Healthcare delivery is labor intensive; wage inflation and staffing shortages can erode care-team efficiency and outcomes.
  • Execution and expansion risk: Geographic or program growth can strain operations if care delivery, compliance, and risk management practices do not scale proportionately.

📊 Valuation & Market View

Market valuation for senior healthcare services and program-based providers often reflects a blend of healthcare services multiples and managed-care-like risk perception. Investors typically anchor on EV/EBITDA and P/S, with the key emphasis on:

  • Durability of reimbursement: strength of program participation and contract continuity.
  • Margin trajectory: the ability to sustain or improve margins while investing in care capacity and compliance.
  • Quality outcomes and risk management: evidence that utilization and costs are controlled without compromising quality metrics.
  • Operating leverage: whether scale translates into better unit economics across membership and service lines.

Multiple expansion generally requires confidence in care model effectiveness, stable government economics, and credible execution of expansion and staffing plans.

🔍 Investment Takeaway

InnovAge’s long-term investment case rests on an integrated, regulator-dependent care model that can be difficult to replicate: regulatory participation creates meaningful barriers to entry, while continuous care coordination supports quality and cost-of-care discipline in program-linked reimbursement structures. The central question for sustained value creation is whether care outcomes, utilization management, and compliance execution can scale while absorbing reimbursement and labor cost volatility.


⚠ AI-generated — informational only. Validate using filings before investing.

```

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for INNV.

globenewswire.com2026-05-12

InnovAge Appoints Jennifer Browne as President and Chief Operating Officer

DENVER, May 12, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced that Jennifer Browne has been appointed President and Chief Operating Officer, effective June 8, 2026. Ms. Browne brings deep experience leading complex, multi-state healthcare organizations operating under value-based care models.

seekingalpha.com2026-05-05

InnovAge Holding Corp. (INNV) Q3 2026 Earnings Call Transcript

InnovAge Holding Corp. (INNV) Q3 2026 Earnings Call Transcript

zacks.com2026-05-05

InnovAge Holding Corp. (INNV) Reports Q3 Loss, Beats Revenue Estimates

InnovAge Holding Corp. (INNV) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.08 per share a year ago.

globenewswire.com2026-05-05

InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2026

DENVER, May 05, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal third quarter ended March 31, 2026. We delivered a solid third quarter, reflecting continued improvement in operating execution and financial performance,” said Patrick Blair, Chief Executive Officer of InnovAge.

zacks.com2026-05-04

Can Strong Growth Aid INNV's Q3 Earnings Amid Margin Seasonality?

InnovAge heads into fiscal Q3 earnings with strong growth momentum and margin gains, but seasonal cost pressures and fading Medicaid tailwinds may temper near-term upside.

globenewswire.com2026-04-21

InnovAge to Announce Fiscal Third Quarter 2026 Financial Results and Host Conference Call Tuesday, May 5, 2026

DENVER, April 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2026 fiscal third quarter financial results on Tuesday, May 5, 2026, after market close. In conjunction, the Company will host a conference call to review the results at 5 p.m.

zacks.com2026-04-06

Take the Zacks Approach to Beat the Markets: Stride, InnovAge, PepsiCo in Focus

LRN's surge, INNV's upgrade-driven rally and PEP's steady gains showcase how Zacks strategies are outperforming despite ongoing market volatility.

zacks.com2026-03-18

New Strong Buy Stocks for March 18th

NWPX, INNV, WGS, BCBP and BWXT have been added to the Zacks Rank #1 (Strong Buy) List on March 18, 2026.

zacks.com2026-03-16

3 Medical Service Industry Stocks Set to Counter Workforce Issues

BTSG, INNV and PACS could benefit as the medical services industry embraces digital health and analytics, though workforce shortages still pressure providers.

zacks.com2026-03-13

All You Need to Know About InnovAge (INNV) Rating Upgrade to Strong Buy

InnovAge (INNV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

zacks.com2026-03-12

InnovAge (INNV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

InnovAge (INNV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

zacks.com2026-03-06

New Strong Buy Stocks for March 6th

TFPM, NEM, INNV, MGA and HAYW have been added to the Zacks Rank #1 (Strong Buy) List on March 6, 2026.

zacks.com2026-02-26

Earnings Estimates Moving Higher for InnovAge (INNV): Time to Buy?

InnovAge Holding Corp. (INNV) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

defenseworld.net2026-02-24

InnovAge (NASDAQ:INNV) Stock Price Up 8.5% Following Analyst Upgrade

InnovAge Holding Corp. (NASDAQ: INNV - Get Free Report) traded up 8.5% on Monday after JPMorgan Chase and Co. raised their price target on the stock from $5.00 to $7.00. JPMorgan Chase and Co. currently has an underweight rating on the stock. InnovAge traded as high as $8.80 and last traded at $8.8540. 49,382 shares traded

seekingalpha.com2026-02-23

InnovAge: The Headwinds Are Priced In, The Growth May Not Be

InnovAge Holding Corp. delivers strong operational execution, driving significant revenue and margin expansion through its PACE model for elderly care. INNV's revenue rose 14.7% year-over-year, fueled by participant growth and capitation rate adjustments across established centers. Disciplined cost management and SG&A reductions have expanded center-level contribution margin to 22% and adjusted EBITDA margin to 9.2%.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"INNV reported Q3’26 (ended 2026-03-31) revenue of $251.9M and net loss of $29.5M (EPS: -$0.22). Revenue rose 5.1% QoQ (from $239.7M in 2025-12-31) and 15.5% YoY (vs. $218.1M in 2025-03-31). However, profitability deteriorated sharply: net income swung from a profit of +$10.6M in the prior quarter to -$29.5M in Q3’26 (QoQ), and is down from -$11.4M a year ago (YoY decline of -$18.1M). Over the last four quarters, margins shifted from positive gross profitability (gross profit margin ~18.7%–21.8% in prior quarters) to negative net margins in Q3’26 (-11.7%), indicating operating expense pressure. Operating cash flow remained positive at $18.1M in Q3’26, but free cash flow slipped to $14.5M as the quarter posted higher net income losses and investing outflows (CapEx ~-$2.4M). Balance sheet liquidity improved: cash & short-term investments rose to $138.6M, while net debt was still negative (net cash) at -$57.1M. Shareholder returns appear strong: price is $8.24 and the 1y_change is +190.1% (>20%), suggesting significant capital appreciation despite earnings volatility. No dividends are paid; buybacks were minimal ($0.03M). Overall, momentum is high, but operating profitability is weakening."

Revenue Growth

Good

Revenue increased 5.1% QoQ (239.7M to 251.9M) and 15.5% YoY (218.1M to 251.9M), with a generally upward trajectory across the four-quarter sequence.

Profitability

Neutral

Net income deteriorated materially: +$10.6M in the prior quarter to -$29.5M in Q3’26 (QoQ), and down vs -$11.4M YoY. Net margin moved from +4.4% (Q2’26) to -11.7% (Q3’26), indicating major margin contraction.

Cash Flow Quality

Neutral

Operating cash flow stayed positive at $18.1M, but net income was negative and free cash flow fell to $14.5M. Dividend payments were $0 and buybacks were immaterial, limiting direct cash-based shareholder support.

Leverage & Balance Sheet

Positive

Liquidity improved: cash & short-term investments increased to $138.6M. The company remains in net cash (-$57.1M net debt) with total equity at $232.8M, supporting resilience despite earnings volatility.

Shareholder Returns

Strong

Total return signal is strong from capital appreciation: 1-year price change is +190.1% (>20% momentum). Dividend yield is 0% and buybacks are negligible, so returns are primarily valuation-driven.

Analyst Sentiment & Valuation

Fair

Price target consensus is $6.8 vs. current ~$8.24, implying the stock trades above consensus expectations. High momentum may be outpacing forward fundamentals.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

INNV delivered a strong Q3 FY2026 with revenue of $251.9M (+15.5% YoY) and adjusted EBITDA of $30.5M, reflecting both higher capitation rates and member-month growth. The core operating improvement is visible in center-level contribution margin at $61.0M (24.2%), up ~550 bps YoY, supported by better-than-expected Medicaid rates and improved Medicare risk scores, alongside medical-cost discipline and reduced permanent nursing facility utilization after in-house pharmacy transition. However, profitability at the GAAP level worsened as corporate G&A rose sharply due to increased litigation liability, resulting in a net loss of $29.9M. Guidance was raised for FY2026 revenue ($950M-$975M) and adjusted EBITDA ($85M-$90M), with de novo losses guided to $11.5M-$13.5M. Looking ahead, management flagged emerging FY2027 Medicaid budget pressure and expects Medicare rates to increase only ~1.5% to 2%, setting up potential top-line headwinds. Offsetting this, AI-driven scheduling and clinical workflow initiatives aim to sustain cost control and improve efficiency while reinforcing quality outcomes.

AI IconGrowth Catalysts

  • California, Colorado, and Florida enrollment expansion driving member-month growth (+6.7% YoY; +0.4% QoQ)
  • Better-than-expected Medicaid rates and favorable Medicare risk scores improving revenue in-year
  • Center-level contribution margin expansion from operating execution and cost discipline (24.2% margin; +~550 bps YoY)

Business Development

  • Hospital partnerships in Florida and California (proof of concept described as positive; calibration still required)
  • Potential M&A approach: bolt-on acquisitions of smaller PACE programs to de-risk de novo and shorten capital payback versus pure de novo
  • Policy modernization push via industry association to simplify enrollment and make it easier for seniors/families to choose PACE
  • Interest from CMS and CMMI in policy updates/demonstrations (management cited openness to listen)

AI IconFinancial Highlights

  • Revenue: $251.9M (+15.5% YoY) driven by higher capitation rates and member-month growth
  • Center-level contribution margin: $61.0M vs $40.7M; margin 24.2% vs 18.7% (+~550 bps YoY); also +220 bps QoQ to 24.2%
  • Adjusted EBITDA: $30.5M vs $10.8M YoY; margin 12.1% vs 4.9% YoY
  • Net loss: $(29.9)M (net loss of $(0.22) per share) vs $(11.1)M YoY; increase driven by higher corporate G&A from litigation liability
  • External provider costs: $113.2M (+5% YoY); lower cost per participant after transition to in-house pharmacy services partially offset by higher assisted living utilization and annual rate increases
  • Guidance raised (full-year 2026): revenue $950M-$975M; adjusted EBITDA $85M-$90M (ending/adjusted EBITDA outlook tightened upward per management framing)
  • 2026 de novo losses outlook: $11.5M-$13.5M (explicitly guided)

AI IconCapital Funding

  • Balance sheet liquidity: $95.5M cash & cash equivalents plus $43.1M short-term investments
  • Total debt: $69.4M (senior secured term loan, revolver, and finance leases)
  • Cash flow: $18.1M positive operating cash flow in Q3; capex $3.6M

AI IconStrategy & Ops

  • AI pilots for clinical and operational workflows: synthesize participant records for care planning; flag medication interactions/avoidable acute events; optimize scheduling/transportation to reduce cancellations/unused capacity
  • Emphasis on developing outcome-oriented measures (functional trajectory, ability to remain in community, aligning care with participant goals) to mature into formal management metrics
  • Investing for growth via new Florida centers (still maturing; AI and scheduling initiatives positioned as efficiency levers)

AI IconMarket Outlook

  • Medicare FY2027 rate expectation: +~1.5% to +2% (management cited final 2027 notice as more favorable vs initial proposal; V28 transition deferred impact described as larger for MA than PACE)
  • Medicaid FY2027: early indications suggest budget pressures increasing; management expects rate increases may be lower and combined with more modest Medicare could create top-line pressure (no numeric Medicaid % provided)
  • Next detailed rate outlook: on Q4 and FY2026 earnings call in early September (stated timing)

AI IconRisks & Headwinds

  • Medicaid rate pressure risk for FY2027: states facing post-pandemic and broader budget pressures; management cited early indications of increasing budget pressures
  • Potential top-line pressure if Medicaid rates lag medical cost trend alongside more modest Medicare environment (management framed as near-term dynamic)
  • Litigation liability drove corporate G&A higher (corporate G&A $76.5M; +98.3% YoY; +187.6% QoQ) and contributed to net loss widening
  • De novo ramp losses persist (Q3 de novo losses $1.8M; Q3 2025 $3.5M; Q2 2026 $4.7M), with Orlando, Florida referenced

Q&A: Analyst Interest

  • Medicaid vs Medicare rate drivers for Q4/FY2027: Management said FY2027 Medicaid rates are not set yet and states face complex budget backdrops. For FY2026, they cited a step-up in Medicaid rates starting January 1 (notably California) and improved Medicare risk scores as potentially durable unless enrollment mix changes.
  • Cost growth sustainability under a potentially tougher 2027 rate environment: Management reaffirmed confidence in managing inflationary cost trends via AI-enabled clinical and operational efficiency (e.g., scheduling/transportation and reducing cancellations) plus expanded operational value initiatives aimed at taking clinical variation out of the system and improving top-tier license productivity.
  • Growth options prioritization (M&A, partnerships, policy/demonstrations) and tradeoffs with profitability: Management began describing a post-turnaround posture and outlined bolt-on acquisitions to reduce de-risking of de novo, plus Florida/California hospital joint ventures with ongoing calibration, and a policy modernization agenda. The profitability-vs-growth framing response was not completed in the provided transcript.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the INNV Q3 2026 (fiscal third quarter ended March 31, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for INNV.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (INNV)

© 2026 Stock Market Info — Innovage Holding Corp. (INNV) Financial Profile